CRISPR Therapeutics (CRSP) said Thursday that new phase 1 clinical data for its treatment CTX310 continues to demonstrate dose-dependent reductions in triglycerides and low-density lipoprotein, which are recognized risk factors for atherosclerotic heart disease.

The data showed peak reduction of up to 82% in triglycerides and up to 86% in low-density lipoprotein, with a well-tolerated safety profile, the company said.

CRISPR said it expects to present complete phase 1 data of CTX310, which targets the ANGPTL3 gene, at a medical meeting in H2.

The company said it also expects an update for its phase 1 trial of CTX320 in H1 2026. The investigational treatment targets the LPA gene in patients with elevated lipoprotein, a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events.